Navigation Links
GeneCards(R) Version 3.0 Beta Released

CAMBRIDGE, Mass., May 13 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today a major leap for GeneCards(R) with the release of Version 3.0 beta, available at

The new GeneCards Version 3.0 features a significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It provides capabilities for highly effective and well-targeted queries, a user-friendly display and clear data navigation. Also released is a preliminary version of GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes.

Dr. David Warshawsky, President and CEO of Xennex, stated: "We are delighted to see the outstanding progress resulting from our partnership with the GeneCards team at the Weizmann Institute of Science. GeneCards Version 3.0 is a major milestone that will enable users around the world to better perform cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."

Xennex is providing its commercial users with access to the new GeneCards Version 3.0 beta relational database. With GeneCards Version 3.0, Xennex' customers will be able to integrate GeneCards data into their internal systems, and perform comprehensive data mining.

About GeneCards(R)

GeneCards(R) ( is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.

About Xennex

Founded in 2003, Xennex, Inc. ( is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex' customers include many of the world's leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.

    For further information, please contact:

    Xennex, Inc.
    David Warshawsky, Ph.D.
    Chief Executive Officer
    Tel: +1 617 497 7774

This release was issued through eReleases(TM). For more information, visit

SOURCE Xennex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
2. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
3. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
4. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
5. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
6. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
7. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
8. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
9. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
10. Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem ... and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention ... Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global ... Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP ... a world-class team of qualified medical researchers and practitioners, experienced in administering stem ...
(Date:11/30/2015)... interventional radiology technique shows promise for helping morbidly obese patients ... being presented today at the annual meeting of the Radiological ... --> --> Gastric artery ... a way to stop bleeding in emergency situations, but the ... obesity is new. Mubin Syed , M.D., interventional ...
(Date:11/30/2015)... , December 1, 2015 Partnership includes an ... for the u niversity , ... support treatment s cale - up ... (ARVs)   Africa , where licensees based anywhere in the ... on SDN technology. --> Africa , where licensees based anywhere ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
Breaking Biology News(10 mins):